1
|
The prognostic significance of patient-reported outcomes in cancer clinical trials.
|
J Clin Oncol
|
2008
|
3.14
|
2
|
An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer.
|
Eur J Cancer
|
2008
|
1.95
|
3
|
Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards.
|
Qual Life Res
|
2012
|
1.62
|
4
|
Transfusions at home in patients with myelodysplastic syndromes.
|
Leuk Res
|
2012
|
1.59
|
5
|
Health-related quality of life in survivors of locally advanced breast cancer: an international randomised controlled phase III trial.
|
Lancet Oncol
|
2005
|
1.48
|
6
|
Do quality-of-life randomized clinical trials support clinicians in their decision-making?
|
J Clin Oncol
|
2002
|
1.45
|
7
|
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study.
|
Ann Surg
|
2011
|
1.16
|
8
|
The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative.
|
Health Qual Life Outcomes
|
2013
|
1.08
|
9
|
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
|
J Clin Oncol
|
2007
|
1.08
|
10
|
Development of an EORTC quality of life phase III module measuring cancer-related fatigue (EORTC QLQ-FA13).
|
Psychooncology
|
2012
|
1.01
|
11
|
EORTC QLQ-INFO26: a questionnaire to assess information given to cancer patients a preliminary analysis in eight countries.
|
Psychooncology
|
2007
|
0.98
|
12
|
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
|
Cancer Lett
|
2010
|
0.98
|
13
|
Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia.
|
Blood
|
2013
|
0.98
|
14
|
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study.
|
J Clin Oncol
|
2007
|
0.97
|
15
|
Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials.
|
J Clin Oncol
|
2003
|
0.97
|
16
|
Health related quality of life in Middle Eastern children with beta-thalassemia.
|
BMC Blood Disord
|
2012
|
0.95
|
17
|
Health-related quality of life and symptom assessment in clinical research of patients with hematologic malignancies: where are we now and where do we go from here?
|
Haematologica
|
2007
|
0.93
|
18
|
Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden.
|
Haematologica
|
2014
|
0.90
|
19
|
Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
0.90
|
20
|
Different perception of surgical risks between physicians and patients undergoing laparoscopic cholecystectomy.
|
Surg Laparosc Endosc Percutan Tech
|
2009
|
0.89
|
21
|
Health-related quality of life outcomes in disease-free survivors of mid-low rectal cancer after curative surgery.
|
Ann Surg Oncol
|
2008
|
0.87
|
22
|
Toward a clearer understanding of the prognostic value of health-related quality-of-life parameters in breast cancer.
|
J Clin Oncol
|
2005
|
0.87
|
23
|
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, Investigational Drug Branch for Breast Cancer and the New Drug Development Group Study.
|
J Clin Oncol
|
2004
|
0.87
|
24
|
Standards are needed for quality of life clinical trials.
|
BMJ
|
2002
|
0.83
|
25
|
Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma.
|
Support Care Cancer
|
2012
|
0.83
|
26
|
Health-related quality of life, faecal continence and bowel function in rectal cancer patients after chemoradiotherapy followed by radical surgery.
|
Support Care Cancer
|
2009
|
0.83
|
27
|
Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26.
|
Qual Life Res
|
2012
|
0.80
|
28
|
Health-related quality of life and symptom assessment in patients with myelodysplastic syndromes.
|
Expert Rev Hematol
|
2009
|
0.80
|
29
|
Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.
|
Blood
|
2014
|
0.80
|
30
|
Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
|
Leuk Res
|
2012
|
0.79
|
31
|
Cross-cultural development of the EORTC QLQ-SWB36: a stand-alone measure of spiritual wellbeing for palliative care patients with cancer.
|
Palliat Med
|
2012
|
0.79
|
32
|
Implementing patient-reported health-related quality-of-life data in cancer routine practice to improve accuracy of prognosis. Are we there yet?
|
Expert Rev Pharmacoecon Outcomes Res
|
2009
|
0.78
|
33
|
Using patient-reported health status to improve prognostic assessment in patients with acute myeloid leukemia: current challenges and future applications.
|
Haematologica
|
2013
|
0.78
|
34
|
Motor disability in the setting of oral anticoagulant therapy.
|
Int J Hematol
|
2011
|
0.78
|
35
|
Asking patients with hematological malignancies: 'how do you feel?' Does it really provide independent prognostic information for survival?
|
Eur J Haematol
|
2009
|
0.77
|
36
|
Reassessing the approach to informed consent: the case of unrelated hematopoietic stem cell transplantation in adult thalassemia patients.
|
Philos Ethics Humanit Med
|
2014
|
0.77
|
37
|
Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
|
Leuk Res
|
2012
|
0.77
|
38
|
The prevention of oral mucositis in patients with blood cancers: current concepts and emerging landscapes.
|
Cardiovasc Hematol Agents Med Chem
|
2012
|
0.76
|
39
|
Variability and sample size requirements for health-related quality-of-life measures: understanding the challenges facing investigators.
|
J Clin Oncol
|
2005
|
0.75
|
40
|
Pregnancy in acute promyelocytic leukaemia after front-line therapy with arsenic trioxide and all-trans retinoic acid.
|
Br J Haematol
|
2014
|
0.75
|
41
|
Pain management in hematological patients with major organ dysfunctions and comorbid illnesses.
|
Cardiovasc Hematol Agents Med Chem
|
2012
|
0.75
|
42
|
External beam radiotherapy in prostate cancer patients: short- and long-term health-related quality of life issues.
|
Expert Rev Pharmacoecon Outcomes Res
|
2003
|
0.75
|
43
|
Cultural issues in assessing quality of life in cancer clinical trials.
|
Expert Rev Pharmacoecon Outcomes Res
|
2002
|
0.75
|
44
|
The added value of propensity score matching when using health-related quality of life reference data.
|
Stat Med
|
2013
|
0.75
|